Skip to main content
Fig. 2 | Trials

Fig. 2

From: A phase I, open-label trial on the safety and immunogenicity of the adjuvanted tuberculosis subunit vaccine H1/IC31® in people living in a TB-endemic area

Fig. 2

QuantifERON-TB Gold-in-tube assay conversion after H1/IC31® vaccinations. Blood samples for the Quantiferon-TB Gold-in-tube assay were taken prior to administration of the first H1/IC31® vaccination (study day 0) and at final visit (study day 224). Each dot indicates the IFN-γ concentration (IU/ml) for each study participant prior to, and after, study vaccinations in groups 1, 2, 3 and 4. A horizontal dotted line represents the cutoff value for Quantiferon positivity. The p values between day 0 and 224 were calculated by the Wilcoxon matched-pairs signed rank test

Back to article page

Trials

ISSN: 1745-6215